**STRATEGIC NETWORKING DAY ON BIOSIMILARS**

**24th September 2015**

|  |  |  |
| --- | --- | --- |
| **Timings** | **Schedule** | **Leading Session** |
| 09.00 - 09.45 | Registration |  |
| 09.45 - 10.00 | Welcome | Professor Stephen Chapman  *Keele University* |
| 10.00 – 10.30 | Biosimilars –The view from APBI Biologic Medicines Access Group | TBC |
| 10.30 - 11.00 | Biosimilars – The view from NHS procurement | Margaret Dolan  *NHS Commercial Solutions* |
| 11.00 – 11.30 | How have organisations responded to Biosimilars for Filgrastim and Infliximab.  Discussion in Groups | Professor Ray Fitzpatrick  *Keele University* |
| Refreshment Break | | |
| 11.45 – 12.15 | Feedback from Groups: What were the Issues/Challenges | Professor Ray Fitzpatrick  *Keele University* |
| 12.15 – 12.45 | Insulin Glargine its place in therapy | Clinical Speaker TBC |
| 12.45 – 13.45 | Biosimilar Insulin Glargine | Margaret Dolan  *NHS Commercial Solutions* |
| Lunch | | |
| 14.00 – 14.15 | Glargine use in primary and secondary care in the West Midlands | Professor Ray Fitzpatrick  *Keele University* |
| 14.15 – 14.45 | Group Work Local Approach to Insulin Glargine Biosimilar | Professor Ray Fitzpatrick  *Keele University* |
| 14.45 – 15.15 | Feedback / Action Plans | Professor Ray Fitzpatrick  *Keele University* |
| 15.15 - 15.45 | Open Forum for Chief Pharmacists and HOMM’s | Professor Ray Fitzpatrick  *Keele University* |
| Close | | |